Pulmonology

Sleep fragmentation in obstructive sleep apnea is measured by the number of EEG arousals per hour of sleep but new data from SLEEP 2023 dive deeper into the intensity of arousals.

The higher severity of obstructive sleep apnea is associated with an increased risk of dementia, according to data from SLEEP 2023.

The team aimed to examine the impact surgical treatment of obstructive sleep apnea had on periodic limb movement index in pediatric patients.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

As a result of these practices, asthma disparities have been amplified due to the concentration of poverty, heightened exposure to environmental hazards, and inadequate housing quality in these communities.

The increased use of tobacco-free nicotine products highlights the need for physicians to stay informed about nicotine pouches and be prepared for discussions with their patients.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.